Copper
Copper (Cu)
An essential trace mineral required for iron metabolism, connective tissue formation, and antioxidant enzyme function.
Copper is an essential trace mineral involved in numerous enzymatic reactions. It's critical for iron metabolism (ceruloplasmin), energy production (cytochrome c oxidase), connective tissue synthesis (lysyl oxidase), and antioxidant defense (superoxide dismutase). Copper must be balanced with zinc, as high zinc intake can deplete copper. Most people get adequate copper from diet, but supplementation may be needed when taking high-dose zinc.
Mechanisms of Action
Iron Metabolism
Essential for iron transport and utilization
Antioxidant Defense
Component of superoxide dismutase
Connective Tissue
Required for collagen cross-linking
Recommended Dose
1-2mg daily (typically to balance zinc)
Loading: Not required; maintain consistent intake
Optimal Timing
- With food to reduce GI upset
- Separate from zinc by 2+ hours if taking both
Take with food
Best Form
Copper Bisglycinate (gentle, well-absorbed)
Alternatives: Copper Gluconate, Copper Citrate, Cupric Oxide (poorly absorbed)
Chelated forms like bisglycinate are gentler. Avoid copper oxide due to poor absorption.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Often taken at a 15:1 ratio with zinc (e.g., 30mg zinc with 2mg copper). Don't exceed needs.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Zinc Balance
Prevents zinc-induced copper deficiency
Energy Support
Supports mitochondrial energy production
Toxicity Risk
Excess copper can be harmful
Add 1-2mg copper to prevent deficiency
Who Should NOT Take This
- Wilson's disease (copper accumulation disorder)
- Hereditary copper toxicity conditions
Drug Interactions
High zinc depletes copper; balance needed
Chelates copper; used for Wilson's disease
Possible Side Effects
Tip: Take with food; use chelated forms
Tip: Don't exceed recommended doses; avoid if Wilson's disease
Warnings
- Most people get enough from diet
- Wilson's disease patients must avoid copper
- Balance with zinc is essential
Top studies from 40+ peer-reviewed papers
Zapata LB et al. • The Cochrane database of systematic reviews (2025)
“Evidence from RCTs of women seeking routine IUD placement suggests that receiving misoprostol compared to placebo or no treatment makes little to no difference to pain during tenaculum placement or after IUD placement; and may make little to no difference to pain during IUD placement.”
Key Findings:
- Misoprostol may result in little to no difference in pain during IUD placement (MD -0.47, 95% CI -1.23 to 0.29; 7 RCTs, 766 women; low-certainty evidence).
- Providers' ease of placement: misoprostol may result in little to no difference in a clinically meaningful effect on ease of IUD placement for providers (MD -0.89, 95% CI -1.55 to -0.22; 8 RCTs, 848 women; low-certainty evidence).
- Need for cervical dilation: misoprostol may result in little to no difference in need for cervical dilation for women without a recent failed placement attempt (RR 0.84, 95% CI 0.38 to 1.85; 6 RCTs, 562 women; low-certainty evidence).
- Misoprostol probably results in little to no difference in need for cervical dilation for women with a recent failed placement attempt (RR 0.88, 95% CI 0.56 to 1.36; 1 RCT, 90 women; moderate-certainty evidence).
Turner S et al. • The Cochrane database of systematic reviews (2021)
“Most interventions were assessed by single, small studies.”
Key Findings:
- Fixed appliances and auxiliaries One study found that use of a lip bumper may reduce crowding in the early permanent dentition (MD -4.39 mm, 95% CI -5.07 to -3.71; 34 participants).
- One study concluded that coaxial nickel-titanium (NiTi) archwires may cause more tooth movement in the lower arch than single-stranded NiTi archwires (MD 6.77 mm, 95% CI 5.55 to 7.99; 24 participants).
- Another study, comparing copper NiTi versus NiTi archwires, found NiTi to be more effective for reducing crowding (MD 0.49 mm, 95% CI 0.35 to 0.63, 66 participants).
- Meta-analysis of two studies showed no evidence that adding vibrational appliances to fixed appliances reduces crowding at 8 to 10 weeks (MD 0.24 mm, 95% CI -0.81 to 1.30; 119 participants).
Shen J et al. • The Cochrane database of systematic reviews (2019)
“Levonorgestrel and mid-dose mifepristone (25 mg to 50 mg) were more effective than Yuzpe regimen.”
Key Findings:
- Levonorgestrel users were less likely to have any side effects than Yuzpe users (RR 0.80, 95% CI 0.75 to 0.86; 1 RCT, n = 1955, high-quality evidence).
- UPA users were more likely than levonorgestrel users to have resumption of menstruation after the expected date (RR 1.65, 95% CI 1.42 to 1.92, 2 RCTs, n = 3593, I2 = 0%, high-quality evidence).
- Levonorgestrel and mid-dose mifepristone (25 mg to 50 mg) were more effective than Yuzpe regimen.
- Mifepristone low dose (less than 25 mg) was less effective than mid-dose mifepristone.
Ryan A et al. • The Cochrane database of systematic reviews (2019)
“The cut-offs used for caeruloplasmin, 24-hour urinary copper and hepatic copper for diagnosing Wilson's disease are method-dependent and require validation in the population in which such index tests are going to be used.”
Key Findings:
- The cut-offs used for caeruloplasmin, 24-hour urinary copper and hepatic copper for diagnosing Wilson's disease are method-dependent and require validation in the population in which such index tests are going to be used.
- Binary cut-offs and use of single-test strategies to rule Wilson's disease in or out is not supported by the evidence in this review.
- There is insufficient evidence to inform testing in specific subgroups, defined by age, ethnicity or clinical subgroups.
Lopez LM et al. • The Cochrane database of systematic reviews (2015)
“Nearly all trials used modern IUC.”
Key Findings:
- Here we synthesize results from trials with sufficient outcome data and moderate- or high-quality evidence.For lidocaine, meta-analysis showed topical 2% gel had no effect on pain at tenaculum placement (two trials) or on pain during IUC insertion (three trials).
- Mean score for IUC-insertion pain was lower with lidocaine and prilocaine cream (MD -1.96, 95% CI -3.00 to -0.92).
- Among nulliparous women, topical 4% formulation showed lower scores for IUC-insertion pain assessed within 10 minutes (MD -15.90, 95% CI -22.77 to -9.03) and at 30 minutes later (MD -11.10, 95% CI -19.05 to -3.15).
- Among parous women, IUC-insertion pain was lower with 10% spray (median 1.00 versus 3.00).
Study Type Distribution
Goals This Supplement Supports
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.